<DOC>
	<DOCNO>NCT02633033</DOCNO>
	<brief_summary>This observational study aim characterize patient population describe multiple sclerosis exacerbation recovery , treatment pattern safety outcomes patient multiple sclerosis experience exacerbation treat H.P . Acthar® Gel ( Acthar Gel ) standard practice United States .</brief_summary>
	<brief_title>Observational Registry H.P . Acthar® Gel Multiple Sclerosis Relapse</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<criteria>1 . Male Female ≥ 18 year age . 2 . Patient clinically definite relapse form Multiple Sclerosis accord McDonald Criteria ( 2010 revision ) . 3 . Patient acute MS exacerbation determine treat clinician . 4 . Patient plan initiate Acthar Gel treatment acute MS exacerbation . 5 . Patient capable providing inform consent . 1 . Patients diagnosis Progressive MS. 2 . Patients require concomitant corticosteroid therapy . 3 . Patients receive experimental drug therapy . 4 . Patients history scleroderma , systemic fungal infection , ocular herpes simplex , cancer within prior 5 year . 5 . Patients recent surgery history presence peptic ulcer within 6 month prior study entry , congestive heart failure , sensitivity protein porcine origin . 6 . If female , pregnant breastfeeding ; , childbearing age , unwillingness use appropriate birth control .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>